Alicia Lorenzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alicia Lorenzo has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Manuel Monreal
Thromboembolic Disease, Faculty of Health Sciences, UCAM - Universidad Católica San Antonio de Murcia, Murcia; CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain
2 shared publications- Manuel Quintana-Díaz
Doctoral Program in Medicine and Surgery, University Autonomous of Madrid
2 shared publications the RIETE Investigators
Italy
2 shared publicationsAdriana Visonà
Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain
1 shared publicationAida Gil-Diaz
Department of Internal Medicine, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria; Universidad de Las Palmas de Gran Canaria, Spain
1 shared publication- Alberto Manuel Borobia
Clinical Pharmacology Department, La Paz University Hospital-IdiPAZ, School of Medicine, Autonomous University of Madrid, 28046 Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 28 August 2026
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 5 (3) , 1-8
Clinical characteristics, prescription patterns and clinical outcomes of patients with extended therapy with direct oral anticoagulants for unprovoked venous thromboembolism
Background: Extended therapy with direct oral anticoagulants (DOACs) is common for managing unprovoked venous thromboembolism (VTE), but real-world data on dosing decisions and their association with outcomes are limited. Methods: From April 2013 to September 2023, we identified patients with unprovoked VTE in the RIETE registry who survived the first 6 months without recurrent VTE or major bleeding. We examined predictors of reduced- vs. full-dose DOACs (rivaroxaban or apixaban) and the association between dosing and recurrent VTE and major bleeding. Logistic regression was used to identify predictors of dosing and competing-risk regression models to identify predictors of outcomes. Results: Among 3749 patients undergoing extended DOAC therapy, 921 (25%) received reduced doses. Predictors of reduced-dose use included age >75 years [adjusted odds ratio (aOR): 1.74; 95%CI: 1.48-2.05], body weight <60 kg (aOR: 1.36; 95%CI: 1.08-1.71), renal failure (aOR: 1.78; 95%CI: 1.41-2.24), and apixaban (vs. rivaroxaban) use (aOR: 2.33; 95%CI: 1.80-3.00). Over a median of 240 days, among all 3749 patients, 44 developed VTE recurrence and 15 bled. Apixaban (vs. rivaroxaban) use [adjusted hazard ratio (aHR): 0.42; 95%CI: 0.40-0.45] and antiplatelet therapy (aHR: 1.72; 95%CI: 1.68-1.77) were associated with VTE recurrence. Male sex (aHR: 0.70; 95%CI: 0.65-0.76), weight <60 kg (aHR: 2.02; 95%CI: 1.91-2.14), renal failure (aHR: 2.76; 95%CI: 2.72-2.81), reduced- (vs. full-dose) DOACs (aHR: 0.83; 95%CI: 0.80-0.87) and antiplatelet use (aHR: 8.18; 95%CI: 7.89-8.47) were associated with major bleeding. Conclusions: We highlight a mismatch between dosing decisions and clinical outcomes, suggesting a need for more outcome-focused strategies in DOAC prescribing.
- 28 August 2026
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 5 (3) , 1-8
Open AccessClinical characteristics, prescription patterns and clinical outcomes of patients with extended therapy with direct oral anticoagulants for unprovoked venous thromboembolism
Background: Extended therapy with direct oral anticoagulants (DOACs) is common for managing unprovoked venous thromboembolism (VTE), but real-world data on dosing decisions and their association with outcomes are limited. Methods: From April 2013 to September 2023, we identified patients with unprovoked VTE in the RIETE registry who survived the first 6 months without recurrent VTE or major bleeding. We examined predictors of reduced- vs. full-dose DOACs (rivaroxaban or apixaban) and the association between dosing and recurrent VTE and major bleeding. Logistic regression was used to identify predictors of dosing and competing-risk regression models to identify predictors of outcomes. Results: Among 3749 patients undergoing extended DOAC therapy, 921 (25%) received reduced doses. Predictors of reduced-dose use included age >75 years [adjusted odds ratio (aOR): 1.74; 95%CI: 1.48-2.05], body weight <60 kg (aOR: 1.36; 95%CI: 1.08-1.71), renal failure (aOR: 1.78; 95%CI: 1.41-2.24), and apixaban (vs. rivaroxaban) use (aOR: 2.33; 95%CI: 1.80-3.00). Over a median of 240 days, among all 3749 patients, 44 developed VTE recurrence and 15 bled. Apixaban (vs. rivaroxaban) use [adjusted hazard ratio (aHR): 0.42; 95%CI: 0.40-0.45] and antiplatelet therapy (aHR: 1.72; 95%CI: 1.68-1.77) were associated with VTE recurrence. Male sex (aHR: 0.70; 95%CI: 0.65-0.76), weight <60 kg (aHR: 2.02; 95%CI: 1.91-2.14), renal failure (aHR: 2.76; 95%CI: 2.72-2.81), reduced- (vs. full-dose) DOACs (aHR: 0.83; 95%CI: 0.80-0.87) and antiplatelet use (aHR: 8.18; 95%CI: 7.89-8.47) were associated with major bleeding. Conclusions: We highlight a mismatch between dosing decisions and clinical outcomes, suggesting a need for more outcome-focused strategies in DOAC prescribing.
- Open Access
- 2 January 2024
- Published by MDPI AG in Journal of Vascular Diseases
- Vol. 3 (1) , 1-10
Factors Associated with the Evolution of Superficial Vein Thrombosis and Its Impact on the Quality of Life: Results from a Prospective, Unicentric Study
Background: Superficial venous thrombosis (SVT) is a common clinical condition caused by inflammation and the presence of a thrombus inside a superficial vein. It has traditionally been considered a benign and banal disorder, although it can progress or can be associated with thromboembolic disease of deep territories in up to 20%, asymptomatic or symptomatic pulmonary embolism (PE), especially if it affects the main trunk of the internal saphenous vein. The impact of deep vein thrombosis on the quality of life and its sequelae have long been described in the literature; however, they have not been studied in superficial vein thrombosis. Objectives: We aimed to evaluate the risk factors, management, and complications of SVT and its impact on the quality of life of our patients. Methods: Observational, prospective, single-center study to evaluate the management of SVT. The ultrasound (US) was performed initially on symptomatic patients, during treatment with low-molecular-weight heparin (LMWH), at a follow-up, and at the end of 45 days of treatment. A quality-of-life questionnaire was administered to determine the risk factors, management, and complications of SVT at the moment of diagnosis and at the end of treatment. We included patients referred from the emergency department to a monographic consultation for thromboembolic disease, over 18 years of age with a diagnosis of acute SVT symptomatic, without contraindication to initiate anticoagulation. Results: In total, 63 patients were evaluated between October 2020 and April 2022. The mean age was 65.8 years (SD 13.5), of which 35 were women (55.6%), 39 presented cardiovascular risk factors (61.9%), 25 had a history of previous personal venous thromboembolism (VTE) (39.7%), and 10 had obesity (15.9%), 47 had chronic venous insufficiency or varicose veins (74.9%). During follow-up with ultrasound, 39.7% had partial revascularization, and at discharge, 63.5% had permeabilized the thrombosis against 19% who had residual thrombosis or progression of thrombosis. There was a positive correlation between mobility parameters and improvement in the performance of daily activities (rho = 0.35; p = 0.012) and with improvement in pain/discomfort (rho = 0.37; p = 0.007). An improvement in pain parameters was statistically significantly related to a global assessment health perception (rho = 0.48; p < 0.001). Anxiety and depression parameters were related to a global assessment health perception (rho = 0.462; p = 0.001) and to an overall improvement at 12 months (rho = 0.45; p = 0.001). CONCLUSIONS: Superficial venous thrombosis (SVT) is a highly prevalent disease, which is traditionally considered banal and has good evolution, with heterogeneous management in clinical practice and limited information on patient selection for therapies, current treatment routes, and drug use, as well as outcomes. In recent years, the importance of this entity has become evident due to its frequency in clinical practice, its risk of complications, and the impact it has on the quality of life. This study’s results emphasize the importance of the diagnosis, treatment, and follow-up of superficial venous thrombosis.
- 2 January 2024
- Published by MDPI AG in Journal of Vascular Diseases
- Vol. 3 (1) , 1-10
Open AccessFactors Associated with the Evolution of Superficial Vein Thrombosis and Its Impact on the Quality of Life: Results from a Prospective, Unicentric Study
Background: Superficial venous thrombosis (SVT) is a common clinical condition caused by inflammation and the presence of a thrombus inside a superficial vein. It has traditionally been considered a benign and banal disorder, although it can progress or can be associated with thromboembolic disease of deep territories in up to 20%, asymptomatic or symptomatic pulmonary embolism (PE), especially if it affects the main trunk of the internal saphenous vein. The impact of deep vein thrombosis on the quality of life and its sequelae have long been described in the literature; however, they have not been studied in superficial vein thrombosis. Objectives: We aimed to evaluate the risk factors, management, and complications of SVT and its impact on the quality of life of our patients. Methods: Observational, prospective, single-center study to evaluate the management of SVT. The ultrasound (US) was performed initially on symptomatic patients, during treatment with low-molecular-weight heparin (LMWH), at a follow-up, and at the end of 45 days of treatment. A quality-of-life questionnaire was administered to determine the risk factors, management, and complications of SVT at the moment of diagnosis and at the end of treatment. We included patients referred from the emergency department to a monographic consultation for thromboembolic disease, over 18 years of age with a diagnosis of acute SVT symptomatic, without contraindication to initiate anticoagulation. Results: In total, 63 patients were evaluated between October 2020 and April 2022. The mean age was 65.8 years (SD 13.5), of which 35 were women (55.6%), 39 presented cardiovascular risk factors (61.9%), 25 had a history of previous personal venous thromboembolism (VTE) (39.7%), and 10 had obesity (15.9%), 47 had chronic venous insufficiency or varicose veins (74.9%). During follow-up with ultrasound, 39.7% had partial revascularization, and at discharge, 63.5% had permeabilized the thrombosis against 19% who had residual thrombosis or progression of thrombosis. There was a positive correlation between mobility parameters and improvement in the performance of daily activities (rho = 0.35; p = 0.012) and with improvement in pain/discomfort (rho = 0.37; p = 0.007). An improvement in pain parameters was statistically significantly related to a global assessment health perception (rho = 0.48; p < 0.001). Anxiety and depression parameters were related to a global assessment health perception (rho = 0.462; p = 0.001) and to an overall improvement at 12 months (rho = 0.45; p = 0.001). CONCLUSIONS: Superficial venous thrombosis (SVT) is a highly prevalent disease, which is traditionally considered banal and has good evolution, with heterogeneous management in clinical practice and limited information on patient selection for therapies, current treatment routes, and drug use, as well as outcomes. In recent years, the importance of this entity has become evident due to its frequency in clinical practice, its risk of complications, and the impact it has on the quality of life. This study’s results emphasize the importance of the diagnosis, treatment, and follow-up of superficial venous thrombosis.
- Open Access
- 25 November 2022
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 9, 991376
Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry
Background: Current guidelines recommend the use of direct oral anticoagulants (DOACs) for patients with venous thromboembolism (VTE). However little is known about the use of DOACs in daily practice.Methods: We used the RIETE registry to identify predictors of use of DOACs for initial and/or long-term therapy of VTE based on patient-related factors, institution-related factors or over time.Results: Among 41,678 patients from March 2013 to September 2021, 12,286 (29%) used DOACs: for initial therapy 6,456; for long-term therapy 12,046. On multivariable analysis, independent predictors were: age < 65 years (odds ratio [OR]: 1.30; 95% CI: 1.23–1.38), body weight 120 kg (OR: 0.64; 95% CI: 0.53–0.77), initial VTE presentation as pulmonary embolism (OR: 1.18; 95% CI: 1.13–1.25), recent bleeding (OR: 0.53; 95% CI: 0.45–0.63), renal insufficiency (OR: 0.44; 95% CI: 0.38–0.51), liver cirrhosis (OR: 0.32; 95% CI: 0.20–0.52), thrombocytopenia (OR: 0.40; 95% CI: 0.34–0.49), atrial fibrillation (OR: 1.58; 95% CI: 1.42–1.75) and prior VTE (OR: 1.14; 95% CI: 1.06–1.22). The DOACs were more likely used in other European countries (OR: 8.97; 95% CI: 8.49–9.49), America (OR: 6.35; 95% CI: 5.67–7.11) or in other countries of the world (OR: 2.99; 95% CI: 2.70–3.31) than in Spain, and progressively increased from 2013–2015 to 2016–2018 (OR: 2.78; 95% CI: 2.62–2.95) and 2019–2021 (OR: 6.36; 95% CI: 5.95–6.80).Conclusion: In this large multinational VTE registry, variations were observed in the use of DOACs according to patient or country factors, and over time. The safety, costs, and influence of the DOACs on VTE-related outcomes in daily practice warrant further investigation.
- 25 November 2022
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 9, 991376
Open AccessPredictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry
Background: Current guidelines recommend the use of direct oral anticoagulants (DOACs) for patients with venous thromboembolism (VTE). However little is known about the use of DOACs in daily practice.Methods: We used the RIETE registry to identify predictors of use of DOACs for initial and/or long-term therapy of VTE based on patient-related factors, institution-related factors or over time.Results: Among 41,678 patients from March 2013 to September 2021, 12,286 (29%) used DOACs: for initial therapy 6,456; for long-term therapy 12,046. On multivariable analysis, independent predictors were: age < 65 years (odds ratio [OR]: 1.30; 95% CI: 1.23–1.38), body weight 120 kg (OR: 0.64; 95% CI: 0.53–0.77), initial VTE presentation as pulmonary embolism (OR: 1.18; 95% CI: 1.13–1.25), recent bleeding (OR: 0.53; 95% CI: 0.45–0.63), renal insufficiency (OR: 0.44; 95% CI: 0.38–0.51), liver cirrhosis (OR: 0.32; 95% CI: 0.20–0.52), thrombocytopenia (OR: 0.40; 95% CI: 0.34–0.49), atrial fibrillation (OR: 1.58; 95% CI: 1.42–1.75) and prior VTE (OR: 1.14; 95% CI: 1.06–1.22). The DOACs were more likely used in other European countries (OR: 8.97; 95% CI: 8.49–9.49), America (OR: 6.35; 95% CI: 5.67–7.11) or in other countries of the world (OR: 2.99; 95% CI: 2.70–3.31) than in Spain, and progressively increased from 2013–2015 to 2016–2018 (OR: 2.78; 95% CI: 2.62–2.95) and 2019–2021 (OR: 6.36; 95% CI: 5.95–6.80).Conclusion: In this large multinational VTE registry, variations were observed in the use of DOACs according to patient or country factors, and over time. The safety, costs, and influence of the DOACs on VTE-related outcomes in daily practice warrant further investigation.
- Open Access
- 30 June 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (13) , 2949
Acenocoumarol Pharmacogenetic Dosing Algorithm versus Usual Care in Patients with Venous Thromboembolism: A Randomised Clinical Trial
Patients with venous thromboembolism (VTE) require immediate treatment with anticoagulants such as acenocoumarol. This multicentre randomised clinical trial evaluated the effectiveness of a dosing pharmacogenetic algorithm versus a standard-of-care dose adjustment at the beginning of acenocoumarol treatment. We included 144 patients with VTE. On the day of recruitment, a blood sample was obtained for genotyping (CYP2C9*2, CYP2C9*3, VKORC1, CYP4F2, APOE). Dose adjustment was performed on day 3 or 4 after the start of treatment according to the assigned group and the follow-up was at 12 weeks. The principal variable was the percentage of patients with an international normalised ratio (INR) within the therapeutic range on day 7. Thirty-four (47.2%) patients had an INR within the therapeutic range at day 7 after the start of treatment in the genotype-guided group compared with 14 (21.9%) in the control group (p = 0.0023). There were no significant differences in the time to achieve a stable INR, the number of INRs within the range in the first 6 weeks and at the end of study. Our results suggest the use of a pharmacogenetic algorithm for patients with VTE could be useful in achieving target INR control in the first days of treatment.
- 30 June 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (13) , 2949
Open AccessAcenocoumarol Pharmacogenetic Dosing Algorithm versus Usual Care in Patients with Venous Thromboembolism: A Randomised Clinical Trial
Patients with venous thromboembolism (VTE) require immediate treatment with anticoagulants such as acenocoumarol. This multicentre randomised clinical trial evaluated the effectiveness of a dosing pharmacogenetic algorithm versus a standard-of-care dose adjustment at the beginning of acenocoumarol treatment. We included 144 patients with VTE. On the day of recruitment, a blood sample was obtained for genotyping (CYP2C9*2, CYP2C9*3, VKORC1, CYP4F2, APOE). Dose adjustment was performed on day 3 or 4 after the start of treatment according to the assigned group and the follow-up was at 12 weeks. The principal variable was the percentage of patients with an international normalised ratio (INR) within the therapeutic range on day 7. Thirty-four (47.2%) patients had an INR within the therapeutic range at day 7 after the start of treatment in the genotype-guided group compared with 14 (21.9%) in the control group (p = 0.0023). There were no significant differences in the time to achieve a stable INR, the number of INRs within the range in the first 6 weeks and at the end of study. Our results suggest the use of a pharmacogenetic algorithm for patients with VTE could be useful in achieving target INR control in the first days of treatment.